Generated by Rank Math SEO, this is an llms.txt file designed to help LLMs better understand and index this website.

# Xeraya Capital Sdn. Bhd.: Life Venture

## Sitemaps
[XML Sitemap](https://xeraya.com/sitemap_index.xml): Includes all crawlable and indexable pages.

## Posts
- [Statement By Xeraya](https://xeraya.com/statement-by-xeraya/): Download Announcement in PDF
- [All G Welcomes Xeraya Capital as Strategic Investor to Accelerate Innovation and Growth](https://xeraya.com/all-g-welcomes-xeraya-capital-as-strategic-investor-to-accelerate-innovation-and-growth/): We are delighted to welcome Xeraya Capital as an investor in All G®.  
- [ASEAN Impact Investing at an Inflection Point](https://xeraya.com/asean-impact-investing-at-an-inflection-point/): ASEAN is moving from being an under-allocated impact geography to a more investable regional platform. Globally, the impact investing market reached an estimated $1.571 trillion in assets under management in 2024, with the Global Impact Investing Network estimating a 21% CAGR since 2019. Yet Southeast Asia still attracts only about 3% of global impact capital despite sitting on a regional economy of roughly $3.86 trillion and a population of about 694 million in 2024. That disconnect is the opportunity: the addressable need base is large, the policy stack is maturing, and sector-level demand is becoming commercially legible.
- [Hantavirus: Understanding the Virus That Has the World on Alert](https://xeraya.com/hantavirus-understanding-the-virus-that-has-the-world-on-alert/): In early May 2026, the global public health community was issued a stark reminder of our ongoing vulnerability to zoonotic spillover. A severe respiratory disease cluster emerged aboard the MV Hondius, a Dutch expedition cruise ship navigating back from Antarctica and the South Atlantic. What began as isolated, ambiguous febrile illnesses among passengers rapidly evolved into a confirmed maritime outbreak of hantavirus, specifically identified as the highly lethal Andes virus strain. The World Health Organization (WHO) was officially notified on May 2, 2026, as international containment protocols were triggered. The outbreak resulted in 13 cases (11 laboratory-verified, 2 probable) and three tragic fatalities at sea, setting off a massive international contact tracing campaign across 23 countries.
- [The Microbial Oil Imperative: Why Fermentation-Derived Lipids Represent the Next Frontier in Food, Feed, and Energy Security](https://xeraya.com/the-microbial-oil-imperative-why-fermentation-derived-lipids-represent-the-next-frontier-in-food-feed-and-energy-security/): The 2026 closure of the Strait of Hormuz, described by the International Energy Agency (IEA) as the "greatest global energy security challenge in history," has exposed, with unprecedented severity, the structural fragility of a global lipid economy still anchored to petroleum and a narrow set of vegetable oil monocultures. Against this backdrop, microbial oils derived from oleaginous fungi and yeasts are graduating from laboratory curiosity to an investable industrial platform. 
- [Gene Therapy and Gene Editing – The Next Frontier of Precision Medicine](https://xeraya.com/gene-therapy-and-gene-editing-the-next-frontier-of-precision-medicine/): Historically, the structural paradigm of modern healthcare has been inherently constrained: clinical medicine has overwhelmingly focused on treating symptoms such as managing pain, lowering fevers, or replacing failing organs. This reactive model has frequently fallen short, particularly when confronting complex, incurable genetic anomalies or novel pathogens. 
- [Microbiome Research in Environment and Sustainability: The New Vanguard of Environmental Technology](https://xeraya.com/microbiome-research-in-environment-and-sustainability-the-new-vanguard-of-environmental-technology/): The study of microbiomes, which encompasses the complex and dynamic communities of microorganisms that inhabit virtually every environment on Earth, has historically been confined primarily to the realm of human health and therapeutics. However, a massive paradigm shift is currently underway across the scientific and financial sectors, positioning microbiome research at the vanguard of environmental management, sustainability, and green technology. The urgency of this shift is underscored by the fact that agrifood systems still account for about one-third of anthropogenic greenhouse gas emissions, and methane is responsible for roughly one-third of current warming. Consequently, investors and policymakers are aggressively looking for solutions that can improve productivity while simultaneously reducing environmental pressure. Microbiome research sits squarely in that gap because microbes already drive the natural processes behind soil fertility, waste decomposition, carbon cycling, and water quality. What is changing now is our ability to map, manage, and deploy those microscopic ecosystems with far greater precision.
- [Early Cancer Detection – The Next Growth Engine for the Billion Dollar Diagnostic Industry](https://xeraya.com/early-cancer-detection-the-next-growth-engine/): Recently, the Malaysian Minister of Health (MOH) announced that the annual cost for managing Non-Communicable Diseases (NCDs) is around RM64.3 billion (USD16.5 billion). The shift toward preventive strategies and empowering the public through health system reform will be crucial going forward.
- [Malaysia’s Leadership  in ASEAN 2025 – Unlocking Capital and Innovation for Regional Growth](https://xeraya.com/malaysias-leadership-in-asean-2025-unlocking-capital-and-innovation-for-regional-growth/): As Malaysia shoulders the ASEAN Chairmanship for 2025, Prime Minister Datuk Seri Anwar Ibrahim stands at a critical juncture in regional integration under the theme "Inclusivity and Sustainability". Malaysia's leadership will be instrumental in advancing the ASEAN Community Vision 2045, fostering deeper economic integration, and ensuring equitable development across all member states2. The strategic framework emphasizes collaborative governance, innovative policy solutions, and inclusive economic growth that bridges development gaps, accelerates digital adoption, and establishes robust mechanisms for sustainable trade and investment. Through principled leadership and strategic vision, Malaysia aims to position ASEAN as a unified, resilient regional bloc ready to address 21st-century challenges while maintaining its foundational principles of consensus-building and mutual respect for sovereignty.
- [How Lifesciences is Reshaping Global Markets ](https://xeraya.com/how-lifesciences-is-reshaping-global-markets/): The global economy is entering a new phase in which lifesciences is becoming core economic infrastructure, much like electricity in the industrial age or the internet in the information age. This emerging “bioeconomy” is not just about new drugs or genetically modified crops. It is a broader transformation in how we produce food, treat disease, manufacture materials, manage waste and think about national competitiveness.
- [Impact Investing Malaysia: Catalyzing Change Through Capital](https://xeraya.com/impact-investing-malaysia-catalyzing-change-through-capital/): As global challenges from climate change to public health gaps intensify, investors are beginning to ask for more of their capital. Increasingly, it’s not just about profit but also purpose. This is where impact investing enters the picture: a strategy that seeks measurable social and environmental outcomes alongside financial returns.
- [Funding for Medical Device Startups: What You Need to Know](https://xeraya.com/medical-device-startups-funding-guide/): Medical device startups are at the forefront of transforming patient care, diagnostics, and surgical technologies. However, behind every breakthrough device lies a long and capital-intensive journey, from prototyping and regulatory compliance to scaling and commercialization. According to recent reports, the global MedTech sector is rapidly converging with digital health, demanding even more strategic funding approaches. Yet many innovators face hurdles in raising funds due to strict regulations, long product timelines, and the need for clinical validation. To succeed, startups must understand the funding lifecycle, recognize investor expectations, and navigate market entry barriers. 
- [Venture Capital Meets Islamic Finance Smart Contracts : The Next Leap In Ethical Investing](https://xeraya.com/venture-capital-meets-islamic-finance-smart-contracts/): The global Islamic finance industry has demonstrated remarkable resilience and growth, with assets reaching $5.4 trillion as of 2024. Multiple authoritative sources confirm this expansion trajectory, with Mordor Intelligence projecting the market to reach $9.31 trillion by 2030 at a compound annual growth rate (CAGR) of 11.23%.
- [Joint Venture Agreement (JVA) Between Xeraya Capital SDN. BHD. And Mirxes International Holdings Limited](https://xeraya.com/mou-between-xeraya-capital-and-mirxes-international-holdings-limited/): Xeraya Capital Sdn. Bhd. (via Xeraya Opportunities Fund) and Mirxes International Holdings Limited have entered into a joint venture agreement to establish MyRNA Diagnostics Sdn. Bhd.
- [Xeraya Capital: Malaysia’s Trusted Life Sciences and Pharmaceutical Venture Capital Partner](https://xeraya.com/life-sciences-pharmaceutical-venture-capital/): Southeast Asia is fast becoming a hotbed for pharmaceutical innovation, driven by rising healthcare demands, increased R&D activities, and growing private capital flows into life sciences. In Malaysia, the pharmaceutical sector is entering a pivotal phase, with venture capital and private equity playing a vital role in scaling high-impact companies and breakthrough technologies.
- [2025 Private Investment: Private Equity, Venture Capital, and the Future of High-Growth Investing](https://xeraya.com/private-equity-venture-capital-high-growth-investing/): As the global investment landscape continues to evolve in 2025, two powerful engines are propelling innovation and growth: venture capital (VC) and private equity (PE). While both provide funding to private companies, they differ significantly in focus. Private equity typically targets established businesses with proven models in need of capital for scaling or restructuring, while venture capital supports early-stage, high-potential startups.
- [Why Sustainable Agriculture Investment is the Next Big Opportunity for Impact Investors](https://xeraya.com/sustainable-agriculture-investment-opportunity-impact-investors/): In a world grappling with climate change, population growth, and food insecurity, sustainable agriculture is no longer just an environmental imperative. It’s an investment opportunity with long-term rewards. Forward-thinking investors are turning their focus toward regenerative and resilient food systems that offer both financial returns and social impact. For impact-driven firms like us, sustainable agriculture represents a key area where capital can influence not only portfolio growth, but also global transformation. 
- [The Growing Role of Venture Capital in Shaping Healthcare Innovation](https://xeraya.com/venture-capital-healthcare-innovation/): Healthcare is no longer just a necessity, it’s a strategic investment. Across the globe, venture capital (VC) firms are playing a vital role in accelerating life-changing innovations, from AI-powered diagnostics to biotech breakthroughs and wearable medical devices. Driven by rising global demand for affordable, personalized healthcare and resilient systems, VCs are stepping in to fund bold ideas and guide them from lab to market.
- [How Healthcare Startups Are Revolutionizing the Future of Medicine](https://xeraya.com/healthcare-startups-revolutionizing-future-of-medicine/): Healthcare startups are reshaping the medical landscape by combining cutting-edge technology with human-centric solutions. In recent years, we've witnessed a surge of digital health tools, AI-powered diagnostics, wearable devices, and personalized medicine solutions. All driven by agile, tech-savvy startups determined to solve long-standing healthcare challenges. According to global insights, these startups are not just improving patient care, but also optimizing healthcare systems, increasing accessibility, and redefining the future of medicine. As this dynamic sector grows, investors and stakeholders alike are turning their attention to the innovators behind these changes.
- [Part 2 – Synthetic biology in the context of Southeast Asia](https://xeraya.com/part-2-synthetic-biology-in-the-context-of-southeast-asia/): In Part 1 of this series, we explored how synthetic biology is revolutionizing sustainable development by transforming biology into a tool for engineering life. From generating renewable biofuels using palm oil waste and algae, to producing biodegradable plastics that combat the nation’s plastic crisis, and deploying engineered microbes for environmental remediation, the region is beginning to tap into its natural advantages, abundant biomass, biodiversity, and technical know-how. With real-world applications already underway and pilot projects gaining traction, synthetic biology is no longer theoretical. It’s a powerful enabler of cleaner energy, reduced waste, and greener cities. As we move into Part 2, we turn our attention to the growing ecosystem that supports this innovation, from startups and investments to policy frameworks and the exciting future that lies ahead.
- [Synthetic Biology- Engineering Life for Sustainable Solutions](https://xeraya.com/synthetic-biology-engineering-life-for-sustainable-solutions/): Imagine filling up your car with fuel made from algae, or using a plastic bag that naturally breaks down after a few weeks. These ideas are no longer science fiction as they’re becoming reality thanks to synthetic biology, an emerging field that combines biology and engineering to redesign living organisms for useful purposes. Synthetic biology is being harnessed to address real-world challenges such as creating renewable biofuels, producing biodegradable plastics, and even cleaning up polluted environments. This convergence of science and innovation offers hope for more sustainable development, and in Southeast Asia, particularly Malaysia, with its rich biodiversity and agricultural resources, is poised to benefit.
- [Mirxes achieving a market capitalization exceeding USD 1 billion on its first day of trading on the Hong Kong Stock Exchange (HKEX) marks a monumental milestone](https://xeraya.com/mirxes-achieving-a-market-capitalization-exceeding-usd-1-billion-on-its-first-day-of-trading-on-the-hong-kong-stock-exchange-hkex-marks-a-monumental-milestone/): Congratulations to the entire Mirxes team!Achieving a market capitalization exceeding USD 1 billion on the first day of trading on the Hong Kong Stock Exchange (HKEX) is a monumental milestone.
- [New Frontiers in the Fight Against Antimicrobial Resistance (AMR)](https://xeraya.com/new-frontiers-in-the-fight-against-antimicrobial-resistance-amr/): Antimicrobial resistance (AMR) is a mounting global crisis often referred to as the silent pandemic, already claiming more lives than HIV/AIDS or malaria and projected to cause up to 8 million deaths annually by 2050. Beyond its devastating human toll, AMR threatens to shrink global GDP by nearly 3.8%, posing a dual threat to public health and economic stability. As drug-resistant infections undermine the effectiveness of modern medicine, from surgeries to cancer treatments, the urgency for innovative solutions becomes clear. This document explores the scale and complexity of AMR, the economic and clinical imperatives for action, and the critical role of biotech-driven innovations such as new antibiotics, vaccines, diagnostics, and alternative therapies. It also highlights how Southeast Asia, particularly Malaysia, is emerging as a regional leader through progressive policy, investment, and public-private partnerships. For investors and innovators alike, AMR represents both a pressing challenge and a powerful opportunity to shape the future of global healthcare.
- [What Are GLP-1 Drugs?](https://xeraya.com/what-are-glp-1-drugs/): Pancreas:⬆️ Insulin⬇️ Glucagon
- [Microbiome Healthcare: A Billion-Dollar Opportunity](https://xeraya.com/microbiome-healthcare-a-billion-dollar-opportunity/): The human microbiome, a diverse ecosystem of microorganisms residing in and on the human body, plays a crucial role in maintaining overall health. These microbes, including bacteria, fungi, viruses, and archaea, interact with various biological processes, influencing digestion, metabolism, immune function, and even mental well-being. Recent advancements in microbiome research have shed light on its profound impact on human health, leading to innovations in personalized medicine, functional foods, and disease prevention. An imbalance in microbial composition, known as dysbiosis, has been linked to numerous health conditions, including autoimmune diseases, obesity, and mental disorders. As scientific understanding deepens, microbiome-based therapies and interventions are rapidly transforming healthcare, offering new opportunities for precision medicine, biotechnology investments, and even medical tourism. This article explores the latest developments in microbiome research, its applications in healthcare, and its potential economic and medical impact, particularly in Malaysia.
- [Driving Impact in Southeast Asia: Sustainability and Healthcare Venture Investments in Southeast Asia](https://xeraya.com/driving-impact-in-southeast-asia-sustainability-and-healthcare-venture-investments-in-southeast-asia/): Southeast Asia represents a growing diverse population, with remarkable economic growth potential. ASEAN’s combined GDP makes it the 5th largest economy in the world (after US, China, EU and Japan). The region’s annual GDP has grown by an average of 4.5% since 2010, compared to 3.4% for the world economy; and is expected to continue to outperform the world’s economy through 2029.
- [LIFE SCIENCES INVESTMENT: OPPORTUNITIES IN 2025](https://xeraya.com/life-sciences-investment-opportunities-in-2025/): As 2025 begins, groundbreaking advancements in the field of life sciences continue to emerge, showcasing the immense potential for transformative innovations. For example, researchers have introduced a novel gene-editing tool called SPLICER, which is a modified Nobel-prized CRISPR technology. This technology enables cellular mechanisms to bypass problematic genetic sequences linked to diseases, such as Alzheimer’s. In a recent study published in Nature Communications, the tool demonstrated its ability to reduce amyloid-beta plaque precursors in mice, holding promise not only for Alzheimer’s but also for other diseases.
- [Impact Investing: Why Does It Matter For Malaysia?](https://xeraya.com/impact-investing-why-does-it-matter-for-malaysia/): By Dr Mohamed Eskandar Shah and Dr Anwar Allahpitchay
- [Advancing Sustainability Through Green Hydrogen Innovation](https://xeraya.com/advancing-sustainability-through-green-hydrogen-innovation/): As the world grapples with the urgent need to reduce carbon emissions and combat climate change, hydrogen technology has emerged as one of the pivotal solutions for achieving a sustainable energy future. Hydrogen, a versatile and clean energy carrier, holds the potential to decarbonize sectors that are difficult to electrify, such as heavy industry and transportation. Unlike fossil fuels, hydrogen produces no direct emissions when used, and with the advancement of green hydrogen—produced through renewable energy sources—it promises to be a cornerstone in the global shift towards sustainability. This article explores hydrogen’s role in the energy transition, its production methods, applications, and the challenges and opportunities that lie ahead as the world moves toward a hydrogen-powered future.
- [Monkeypox – Understanding the Current Global Health Threat](https://xeraya.com/monkeypox-understandingthe-current-global-healththreat/): With a total of 103 048 laboratory confirmed cases in 121 countries as of 31 July 2024, and the recent announcement on 14 August 2024 by World Health Organization (WHO) Director General that monkeypox (mpox) constitutes as a public health emergency of international concern (PHEIC), we take a look at this virus to try and understand it better with the information that is available. Furthermore, this is the second time WHO declared mpox as a PHEIC, the first time was in 2022. We will explore the nature of the disease, it’s transmission, symptoms and prevention strategies.
- [Food Security: The Path Towards Self-Sufficiency](https://xeraya.com/food-security-the-pathtowards-self-sufficiency/): Food security is defined as “when all people, at all times, have physical and economic access to sufficient safe and nutritious food that meets their dietary needs and food preferences for an active and healthy life.” According to the Food and Agriculture Organization, four main dimensions of food security can be identified: physical availability of food, economic and physical access to food, food utilization and stability of food supply. For food security objectives to be realized, all four dimensions must be fulfilled simultaneously. With the world's population estimated to reach 9.8 billion people by 2050, food and agriculture are crucial in determining food security. Food and agriculture are both central in shaping food security and nutrition; with food produced and supplied by farmers and fisherfolk needed to be adequate to feed the needs of a growing world population.
- [Embracing Sustainability in Agriculture](https://xeraya.com/embracing-sustainability-in-agriculture/): Agriculture is the world’s largest industry. It is a practice to cultivate natural resources to sustain life and provide economic gains. Agriculture includes cash crops such as rubber, oil palm, and cocoa, crops grown to raise livestock, aquaculture, and the use of raw materials for fossil fuel. The agriculture industry contributes 4.3% to the world’s GDP in 2021 and a quarter of the world's labour force is in agriculture. The employment of more than one billion people generates 9.5 billion tonnes of primary crops that were used as food, feed or materials in products ranging from biofuels to cosmetics. In some least developing countries, agriculture can account for more than 25% of the nation’s GDP. In Malaysia, agriculture used to be the main contributor to our income and foreign exchange with 6.6% of the GDP in 2022. Malaysia’s global agricultural trade reached $61.3 billion in 2022 with exports of USD 37.4 billion and imports of USD 23.9 billion.
- [Playing Our Part in the Innovation Ecosystem](https://xeraya.com/playing-our-part-in-the-innovation-ecosystem/): Penning our thoughts after a few months of interesting announcements made by the Malaysian Government related to funding and priorities for innovation.
- [The Investor’s Edge: Capitalizing on Shariah Compliant Venture Capital](https://xeraya.com/the-investors-edge-capitalizing-on-shariah-compliant-venture-capital/): In the world of value-driven investing, Shariah-compliant strategies are gaining traction among a diverse group of investors. Much like the Environmental, Social, and Governance (ESG) frameworks that have grabbed the attention of the investment community, Shariah principles resonate with a broader audience seeking ethical alignment in their portfolios.
- [Funding the Future: Navigating Malaysia’s Venture Capital Roadmap 2024-2030](https://xeraya.com/funding-the-future-navigating-malaysias-venture-capital-roadmap-2024-2030/): Embarking on a journey towards 2030, the Malaysian Venture Capital Roadmap 2024-2030 (MVCR) presents a transformative blueprint designed to invigorate the nation's innovation ecosystem. As a life science venture capital firm, navigating through this roadmap not only unveils new horizons of opportunity but also underscores our pivotal role in fueling breakthroughs that promise to redefine healthcare, agriculture, and biotechnology landscapes.
- [Flightpath to Sustainability: The Rise of Sustainable Aviation Fuel (SAF)](https://xeraya.com/flightpath-to-sustainability-the-rise-of-sustainable-aviation-fuel-saf-1/): In the face of a rapidly warming planet, the quest for sustainable solutions within the aviation industry has never been more critical. As air travel continues to connect us across continents and with passenger number set to double by 2050, it is a pressing challenge to substantial reduce carbon footprint of air travel. Enter Sustainable Aviation Fuel (SAF) – a ground-breaking innovation poised to revolutionize the skies. This article explores the promise of SAF, an eco-friendly alternative to conventional jet fuel, which stands at the forefront of the aviation industry's fight against climate change. By delving into the science, the success stories, and the strategies for widespread adoption, we uncover the potential of SAF to not only mitigate environmental impact but also to propel the aviation sector towards a more sustainable and resilient future. Join us on this journey through the clouds, where sustainability meets innovation, and discover how SAF is setting the course for a greener horizon.
- [Aria CV Announces First Patient Successfully Implanted with Second-Generation Pulmonary Hypertension System](https://xeraya.com/aria-cv-announces-first-patient-successfully-implanted-with-second-generation-pulmonary-hypertension-system/): SAINT PAUL, Minn.--(BUSINESS WIRE)--Aria CV, Inc, a developer of medical devices treating pulmonary hypertension, today announced the first patient was implanted with the Gen 2 Aria CV Pulmonary Hypertension System as part of the ASPIRE PH clinical trial at Ascension St. Vincent Cardiovascular Research Institute in Indianapolis, Indiana. The implant was completed on February 14, 2024, by Drs. Ashwin Ravichandran and Scott Hittinger.
- [Allecra Therapeutics Announces U.S. FDA Approval for EXBLIFEP® for the Treatment of Complicated Urinary Tract Infections](https://xeraya.com/allecra-therapeutics-announces-u-s-fda-approval-for-exblifep-for-the-treatment-of-complicated-urinary-tract-infections/): SAINT-LOUIS, France & WEILL AM RHEIN, Germany--(BUSINESS WIRE)--Allecra Therapeutics (“Allecra”), a biopharmaceutical company developing novel therapies to combat antibiotic resistance, announced today that the U.S. Food and Drug Administration (FDA) has approved EXBLIFEP® (cefepime/enmetazobactam), as a treatment for complicated urinary tract infections (cUTIs), including pyelonephritis, in patients 18 years and older. Allecra has also received a five-year marketing exclusivity extension from the FDA as part of the Generating Antibiotic Incentives Now Act (GAIN Act). The GAIN Act, enacted by the U.S. Congress, incentivizes the creation of new anti-infective therapeutics by providing benefits to manufacturers of Qualified Infectious Disease Products (QIDPs).
- [Pests of Palm Oil: Steering towards eco-friendly management solutions](https://xeraya.com/pests-of-palm-oil-steering-towards-eco-friendly-management-solutions/): Amidst the lush greenery of Malaysia's heartlands, oil palms stand tall as sentinels of prosperity, anchoring an industry that weaves through the nation's economy. Yet, this agricultural miracle face a silent war against an array of minuscule adversaries—pests that threaten not just yields but the very sustainability of the oil palm legacy. Understanding these challenges and pioneering effective solutions isn't just an agricultural prerogative; it's a matter of national urgency
- [Guardian or Threat? The Story of Neonicotinoid Insecticides](https://xeraya.com/can-we-truly-feed-the-world-without-harming-it-the-dilemma-of-agriculture-technology/): In agriculture, neonicotinoid insecticides have emerged as a pivotal force in the battle against crop-devouring pests, promising bountiful yields and enhanced food security. Yet, the narrative surrounding these chemicals is not one of triumph alone. As we delve into the world of neonicotinoids, we uncover a complex saga marked by controversy and unintended consequences. This article will navigate the dualistic nature of neonicotinoids, examining their role as both protectors of our crops and potential threats to our environment. From the molecular workings that disrupt pests to the global movements aiming to curb their use, we will explore the intricate tapestry of agricultural advances, ecological impacts, and the quest for sustainable solutions. What is the future of this chemical compound that is expected to reach nearly USD $10 billion in value by the year 2025?
- [Biopharma: Thoughts going into 2024](https://xeraya.com/biopharma-thoughts-going-into-2024/): From the peak of both sentiments and valuations in 20/21, driven by the spotlight COVID put in the sector to the strong decline the following years, we came into 2023 with a careful optimism that it will be a year of recovery. Although not near the highs of 20/21, there has been steady momentum within the sector with a strong push right at the end ($31bn worth of deals announced in December 2023). We highlight key topics that will potentially carry-over into 2024.
- [GreenLight Biosciences Announces EPA Registration of Calantha](https://xeraya.com/greenlight-biosciences-announces-epa-registration-of-calantha/): GreenLight Biosciences Secures EPA Registration for new bioinsecticide, Calantha, Historic Step Towards A Safer and More Sustainable Food System  
- [U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)](https://xeraya.com/u-s-federal-circuit-affirms-earlier-ptab-decision-to-invalidate-all-claims-of-united-therapeutics-patent-no-10716793-793-patent/): MORRISVILLE, N.C., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced that the U.S. Court of Appeals for the Federal Circuit (Federal Circuit) today affirmed the earlier decision by the Patent Trial and Appeal Board (PTAB) which found all claims of U.S. Patent No. 10,716,793 (‘793 Patent) to be unpatentable due to the existence of prior art cited by Liquidia in inter partes review (IPR) proceedings. As a result of today’s decision, Liquidia will immediately seek to set aside the injunction issued by the U.S. District Court for the District of Delaware (District Court) in the lawsuit filed by United Therapeutics (UTHR) under the Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act) and pursue final regulatory approval of YUTREPIA by the U.S. Food and Drug Administration (FDA).
- [P2 Science Announces Appointment of Oihana Elizalde as CEO](https://xeraya.com/p2-science-announces-appointment-of-oihana-elizalde-as-ceo/): Green chemistry company P2 Science announced today the appointment of Oihana Elizalde, PhD as Chief Executive Officer effective November 27, 2023.
- [Generating an Efficient Future in the Medical World – The Potential Use Cases for ChatGPT in Healthcare and the Life Sciences](https://xeraya.com/generating-an-efficient-future-in-the-medical-world-the-potential-use-cases-for-chatgpt-in-healthcare-and-the-life-sciences/): Since its debut a year ago, ChatGPT, a text-generating chatbot has shaken up industries the world over, disrupting business with its ability to generate human-like text, essays, and codes with short text prompts. Today, as per TechCrunch, it is being used by 92% of Fortune 500 companies and has hit 100 million weekly active users.
- [Acutus Medical Announces Strategic Realignment of Resources and Corporate Restructuring](https://xeraya.com/acutus-medical-announces-strategic-realignment-of-resources-and-corporate-restructuring/): CARLSBAD, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), today announced a realignment of resources and corporate restructuring.
- [A Planet in Peril: Why the fact that over 40% of Antarctica’s ice shelves have shrunk matters.](https://xeraya.com/a-planet-in-peril-why-the-fact-that-over-40-of-antarcticas-ice-shelves-have-shrunk-matters/): While there are many indicators to hint that climate change is real, one of the biggest ones is the melting of the ice shelves in Antarctica and the Arctic. In this article, Xeraya discusses these natural features, their role in the environment, and why it is crucial that we save the ice from completely melting off the face of this earth.
- [Putting the Pieces Together – iESG Framework Launched to Guide Manufacturers on their Path to Progress](https://xeraya.com/putting-the-pieces-together-iesg-framework-launched-to-guide-manufacturers-on-their-path-to-progress/): Over the past few months, the Malaysian government has released a series of plans that are aimed at furthering the development of the country’s manufacturing industry, including the National Energy Transition Roadmap (NETR) Phase 1, the Chemical Industry Roadmap (CIR 2030), and the National Industrial Master Plan (NIMP 2030). Within the NIMP 2030 specifically, Mission 3 – Push for Net Zero, outlines the specific strategies the government has formulated to tackle a niggling issue for manufacturers globally – compliance to Environmental, Social, and Governance (ESG) standards.
- [The National Energy Transition Roadmap (NETR): A Vision for a Sustainable and Clean Energy Future](https://xeraya.com/the-national-energy-transition-roadmap-netr-a-vision-for-a-sustainable-and-clean-energy-future/): Malaysia's recent National Energy Transition Roadmap (NETR) is a bold and ambitious plan to achieve a sustainable and inclusive energy system by 2050. Launched on 29th August 2023, the NETR outlines six key energy transition levers: decarbonizing the electricity sector, electrifying end-use sectors, enhancing energy efficiency, developing renewable energy sources, promoting sustainable transport, and managing energy demand.
- [NIMP 2030 – 6 Key Sectors to Watch (Part 2)](https://xeraya.com/nimp-2030-6-key-sectors-to-watch-part-2/): The manufacturing industry has long-been a key driver of Malaysia’s economy and is well-recognised as playing a crucial role in the country’s journey towards achieving developed nation status.

## Pages
- [Illume 2026 Edition](https://xeraya.com/illume-publications/illume-2026-edition/)
- [Sik Han Ming](https://xeraya.com/our-team/sik-han-ming/): Investment Associate
- [Life Sciences Venture Capital](https://xeraya.com/life-sciences/): The expansive landscape of Life Sciences is undergoing a phenomenal transformation, fueled by groundbreaking scientific discoveries and global demand for innovative solutions. This sector encompasses everything from novel drug therapies to sustainable bio-based products.
- [Illume 2025 Edition](https://xeraya.com/illume-publications/illume-2025-edition/)
- [Adha Roslan](https://xeraya.com/our-team/adharoslan-2/): Corporate Communications & Investor Relations
- [Illume 2023 Edition](https://xeraya.com/illume-publications/illume-2023-edition/)
- [Industry Updates](https://xeraya.com/industry-updates/): 11 min read
- [Yvonne Lau](https://xeraya.com/board-of-directors/yvonne-lau/): Director
- [MIF Investments Ltd. (MIFIL) Board](https://xeraya.com/mifil-board/): Datuk Dr. Yacob Mustafa is the Accountant General of Malaysia.
- [Board of Directors](https://xeraya.com/board-of-directors/): YBhg. Datuk Prof. Dr. Rofina Yasmin Binti Othman was appointed as Director on the Boards for Xeraya Capital and Xeraya Capital Labuan Ltd as of November 2019.
- [Dr. Ghows Azzam](https://xeraya.com/our-team/ghows-azzam/): Investment Operations & Special Projects
- [Disclaimer](https://xeraya.com/disclaimer/): Last updated: April 28, 2023
- [Terms of Use](https://xeraya.com/terms-of-use/): Last updated: April 28, 2023
- [Media](https://xeraya.com/media/): Xeraya Capital's Company Profile
- [Knowledge Base](https://xeraya.com/knowledge-base/)
- [Slides](https://xeraya.com/knowledge-base/slides/): Slides
- [Infographics](https://xeraya.com/knowledge-base/infographics/): Infographics
- [Events Gallery](https://xeraya.com/events-gallery/): Posted by
Xeraya Admin December 9, 2022
3 min read Xeraya Capital's Annual Dinner 2022 Events Gallery Posted by
Xeraya Admin December 8, 2022
3 min read MVCA Awards 2022 Events Gallery 1
- [News & Events](https://xeraya.com/news-events/): Posted by Xeraya Admin February 19, 2024 13 min read Pests of Palm Oil: Steering towards eco-friendly management solutions Industry Updates Agriculture Technology Posted by Xeraya Admin February 6, 2024 16 min read Guardian or Threat? The Story of Neonicotinoid Insecticides Industry Updates Agriculture Technology Posted by Xeraya Admin January 22, 2024 6 min read Biopharma: Thoughts going into 2024 Updates Posted by Xeraya Admin January 4, 2024 6 min read GreenLight Biosciences Announces EPA Registration of Calantha Biorenewables & Others Posted by Xeraya Admin December 20, 2023 11 min read U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent) Medical Technologies Posted by Xeraya Admin November 27, 2023 4 min read P2 Science Announces Appointment of Oihana Elizalde as CEO Pharmaceutical Biotechnology Posted by Xeraya Admin November 8, 2023 7 min read Acutus Medical Announces Strategic Realignment of Resources and Corporate Restructuring Medical Technologies Posted by Xeraya Admin October 4, 2023 2 min read RNAi pesticide moves closer to US approval Biorenewables & Others Posted by Xeraya Admin September 27, 2023 4 min read InterVenn Biosciences Welcomes Accomplished Diagnostics Executive Joshua Stahl as CEO Medical Technologies Posted by Xeraya Admin August 31, 2023 6 min read Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML Pharmaceutical Biotechnology Posted by Xeraya Admin June 27, 2023 4 min read Allecra Therapeutics Submits New Drug Application to the U.S. FDA for EXBLIFEP® for the Treatment of Complicated Urinary Tract Infections Pharmaceutical Biotechnology Posted by Xeraya Admin June 27, 2023 5 min read Test Based on Glycoproteomic Profiles Shows High Sensitivity for Advanced Adenomas Medical Technologies Posted by Xeraya Admin May 8, 2023 5 min read InterVenn Demonstrates Power of Its GlycoVision Platform In Advanced Adenoma and Colorectal Cancer Medical Technologies Posted by Xeraya Admin March 7, 2023 7 min read GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Plant Health R&D Day Pharmaceutical Biotechnology Posted by Xeraya Admin January 9, 2023 9 min read Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023 Pharmaceutical Biotechnology Posted by Xeraya Admin January 5, 2023 7 min read InterVenn Biosciences Enters Next Stage with Senior Management Team Updates Focused on Commercialization Medical Technologies Posted by Xeraya Admin December 9, 2022 1 min read Xeraya Capital's Annual Dinner 2022 Events Gallery Posted by Xeraya Admin December 8, 2022 1 min read MVCA Awards 2022 Events Gallery Posted by Xeraya Admin December 6, 2022 3 min read Acutus Medical Obtains MDR CE Mark of the AcQMap 3D Imaging and Mapping Catheter Medical Technologies Posted by Xeraya Admin November 22, 2022 3 min read Merck to buy Xeraya-backed Imago BioSciences for $1.35b Pharmaceutical Biotechnology Posted by Xeraya Admin November 3, 2022 3 min read Acutus Medical achieves $20M milestone in Medtronic deal Medical Technologies Posted by Xeraya Admin October 19, 2022 1 min read SIDC's Business Foresight Forum 2022 Highlights Events Gallery Posted by Xeraya Admin October 5, 2022 6 min read Allecra Therapeutics Publishes Final Phase 3 ALLIUM Data in JAMA: Cefepime/ Enmetazobactam Met Criteria for Superiority Pharmaceutical Biotechnology Posted by Xeraya Admin October 5, 2022 6 min read Nobel Prize goes to click chemists who discovered how to snap molecules together 'like Lego' Medical Technologies 123...8
- [Bruce Cohen](https://xeraya.com/our-team/bruce-cohen-2/): Venture Partner
- [Dato’ Hans Peter Brenner](https://xeraya.com/our-team/dato-hans-peter-brenner-2/): Venture Partner
- [Datuk Dr. Abd Hapiz](https://xeraya.com/our-team/datuk-dr-abd-hapiz/): Venture Partner
- [Syaron Tang](https://xeraya.com/our-team/syaron-tang/): Assistant Vice President, Finance
- [Irene Chen](https://xeraya.com/our-team/irene-chen/): Senior Vice President, Reporting & Compliance
- [Norashikin Muhamad](https://xeraya.com/our-team/norashikin-muhamad/): Head of Legal & Company Secretary
- [Alan Cheah](https://xeraya.com/our-team/alan-cheah/): Chief Financial Officer
- [Shafini Abd Hapiz](https://xeraya.com/our-team/shafini-abd-hapiz/): Vice President, Investments
- [Noorhayati M. Nasir](https://xeraya.com/our-team/noorhayati-m-nasir/): Vice President, Investments
- [Goh Wei Ling](https://xeraya.com/our-team/goh-wei-ling/): Senior Vice President, Investments
- [Norazli Mohamad Nor](https://xeraya.com/our-team/norazli-mohamad-nor/): Venture Partner
- [Jason Rushton](https://xeraya.com/our-team/jason-rushton/): Partner, Investments
- [Aditya Puri](https://xeraya.com/our-team/aditya-puri/): Partner, Investments
- [Principles for Responsible Investment (PRI)](https://xeraya.com/our-focus/principles-for-responsible-investment-pri/): We are proud indeed. As of 23rd March 2018, our commitment to the development of a more stable, sustainable, and responsible global financial system became an established goal when we joined a worldwide network of thousands of fellow investors, all of whom have pledged to put the Principles for Responsible Investment (PRI) into practice.
- [Open Innovation Between Our Partners](https://xeraya.com/our-focus/open-innovation/): Open innovation is the modern approach to research and development (R&D). Today's business world is a rapidly evolving environment within which knowledge workers are highly mobile and venture capital is playing an increasingly important role. The incredible speeds at which products change according to rapidly changing customer preferences, as well as the pace of parallel innovations within product markets make it near impossible for any firm to have all the required R&D resources within its own ranks.
- [Dr. Wan Marhaini Wan Ahmad](https://xeraya.com/mifil-board/dr-wan-marhaini-wan-ahmad/): Member, Shariah Advisory Panel
- [Prof. Dr. Engku Rabiah Adawiah Binti Engku Ali](https://xeraya.com/mifil-board/prof-dr-engku-rabiah-adawiah-binti-engku-ali/): Member, Shariah Advisory Panel
- [Prof. Dr. Aznan Hasan](https://xeraya.com/mifil-board/prof-dr-aznan-hasan/): Chairperson, Shariah Advisory Panel
- [Jamaludin Bujang](https://xeraya.com/mifil-board/jamaludin-bujang/): Director, MIFIL Board
- [Dato’ Wan Kamaruzaman Wan Ahmad](https://xeraya.com/mifil-board/dato-wan-kamaruzaman-wan-ahmad/): Director, MIFIL Board
- [Datuk Dr. Yacob Mustafa](https://xeraya.com/mifil-board/datuk-dr-yacob-mustafa/): Chairman, MIFIL Board
- [Chen Wen Yin](https://xeraya.com/board-of-directors/chen-wen-yin/): Director
- [Johan Mohd Roslie](https://xeraya.com/board-of-directors/johan-mohd-roslie/): Director
- [Quek Pei Lynn](https://xeraya.com/board-of-directors/quek-pei-lynn/): Director
- [YBhg. Datuk Prof. Dr. Rofina Yasmin Binti Othman](https://xeraya.com/board-of-directors/prof-dr-rofina-yasmin-othman/): Director
- [Fares Zahir](https://xeraya.com/board-of-directors/fares-zahir/): Director & Chief Executive Officer
- [Our Focus](https://xeraya.com/our-focus/): Investment Focus
- [Our Team](https://xeraya.com/our-team/): Fares Zahir was appointed Chief Executive Officer (CEO) of Xeraya Capital Sdn Bhd in January 2012.
- [Xeraya Home](https://xeraya.com/): Xeraya Capital is a Life Sciences Venture Capital and Private Equity firm in Malaysia that invests in life sciences globally with a focus on driving value locally. Our mission is to catalyse breakthroughs in life sciences and deliver innovations that enhance human well-being.
- [Privacy Policy](https://xeraya.com/privacy-policy/): Last updated: April 28, 2023
- [Illume Publications](https://xeraya.com/illume-publications/): Illume 2026 Edition Illume 2025 Edition Illume 2023 Edition Illume 2022 Edition Illume 2021 Edition Illume 2020 Edition Illume 2019 Edition Illume 2018 Edition

## Real3D Flipbook
- [Illume 2026 Publication](https://xeraya.com/?r3d=illume-2026-publication)
- [Illume 2025 Publication](https://xeraya.com/?r3d=illume-2025-publication)
- [Illume 2023 Publication](https://xeraya.com/?r3d=illume-2023-publication)
- [Illume 2022 Publication](https://xeraya.com/?r3d=illume-2022-publication)
- [2021 Life Sciences Report](https://xeraya.com/?r3d=2021-life-sciences-report)
- [Illume 2021 Publication](https://xeraya.com/?r3d=illume-2021-publication)
- [2020 Life Sciences Report](https://xeraya.com/?r3d=2020-life-sciences-report)
- [Illume 2020 Publication](https://xeraya.com/?r3d=illume-2020-publication)
- [Juggling Genius 2020](https://xeraya.com/?r3d=juggling-genius-2020)
- [Illume 2019 Publication](https://xeraya.com/?r3d=illume-2019-publication)
- [2018 Life Sciences Report](https://xeraya.com/?r3d=2018-life-sciences-report)
- [Illume 2018 Publication](https://xeraya.com/?r3d=illume-2018-publication)